Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.

setidegrasib (ASP3082) - Astellas

Krazati (adagrasib) - BMS

Rasonque (daraxonrasib) - Revolution Medicines

Lumakras (sotorasib) - Amgen

zoldonrasib (RMC-9805) - Revolution Medicines

MRTX1133 - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42720810

Divya Yadav; Hiba Parveen; Madhuri Grover; Nidhi Sharma; Srijita Chatterjee; Swati Arya

Sep 11, 2026